Chris Shibutani
Stock Analyst at Goldman Sachs
(3.22)
# 1,106
Out of 4,944 analysts
96
Total ratings
52%
Success rate
1.19%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $31.55 | +216.96% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.63 | +84.62% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $15.97 | -6.07% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.63 | +11.77% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $112.78 | +21.48% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $13.45 | +145.35% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $309.72 | -2.49% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $36.46 | +39.88% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $174.42 | -11.13% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $8.30 | -51.81% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $9.36 | +113.68% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $660.49 | +9.46% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $19.84 | +31.05% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $131.62 | +16.24% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $201.47 | -14.13% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $25.72 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $47.85 | +44.20% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $20.61 | -36.92% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $36.07 | -36.24% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.85 | +1,654.39% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $40.74 | +27.64% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.16 | +138.47% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $5.32 | +238.66% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $6.88 | +147.09% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.59 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.75 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.30 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $31.55
Upside: +216.96%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.63
Upside: +84.62%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $15.97
Upside: -6.07%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.63
Upside: +11.77%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $112.78
Upside: +21.48%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $13.45
Upside: +145.35%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $309.72
Upside: -2.49%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $36.46
Upside: +39.88%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $174.42
Upside: -11.13%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $8.30
Upside: -51.81%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $9.36
Upside: +113.68%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $660.49
Upside: +9.46%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $19.84
Upside: +31.05%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $131.62
Upside: +16.24%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $201.47
Upside: -14.13%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $25.72
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $47.85
Upside: +44.20%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $20.61
Upside: -36.92%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $36.07
Upside: -36.24%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.85
Upside: +1,654.39%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $40.74
Upside: +27.64%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.16
Upside: +138.47%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $5.32
Upside: +238.66%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $6.88
Upside: +147.09%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.59
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.75
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.30
Upside: -